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Background: Karyotyping is considered the gold standard for the genome-wide detection of genomic imbalances
in prenatal diagnosis, but it has a number of inherent limitations, namely the time required to culture cell and the
limited resolution(5 ~ 10 Mb). Although fluorescence in situ hybridization (FISH) can also be used as a rapid prenatal
diagnosis for common aneuploidies, it is labor intensive, requires prior knowledge of the regions of interest, and
can only be used to diagnose one or a few genomic regions simultaneously. Array comparative genomic
hybridization (aCGH) can overcome the resolution, the locus-specific, and the time limitations of the karyotyping
and FISH techniques and is currently the most powerful method for detecting chromosomal alterations in pre and
postnatal clinical cases. Several investigations have suggested that the aCGH testing should be considered a first-
tier test for the diagnosis of cytogenetic aberrations in the fetus.
Results: This study used karyotyping, FISH, sequence-tagged site (STS) analysis and aCGH to diagnose a case of de
novo duplication of chromosome 21q22.12→ q22.3 with other concomitant deletion and duplication of small
fragments in 21q associated with Down syndrome prenatally.
Conclusions: FISH, aCGH and STS analysis are useful in prenatal investigation of the nature of de novo alterations
of small fragments of the chromosome.
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The most common causes of chromosomal abnormalities
are autosomal aneuploidy (~75%), polyploidy (~13%),
sex chromosomal abnormalities (~8%), and structural
imbalances (~4%) [1,2]. Prenatal testing often includes
fetal chromosome analysis following amniocentesis or
chorionic villus sampling and culturing of the cells
obtained by these invasive procedures. G-banding karyo-
typing of cultured cells has been regarded as the standard* Correspondence: qiqingwei@163.com
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reproduction in any medium, provided the ormethod of prenatal cytogenetic diagnosis. The culturing
process usually takes several days to a few weeks in order
to generate the number of metaphase chromosomes
enough for a reportable karyotype report. Karyotyping has
proved to be highly reliable for the diagnosis of aneu-
ploidies and larger structural rearrangement (>5-10 Mb)
in fetal cells, however, smaller gains or losses of genome
cannot be reliably visualized with karyotyping. The
supremacy of karyotyping in prenatal diagnosis has been
challenged by the introduction of molecular diagnosis
methods including interphase fluorescence in situ
hybridization (FISH) [3]. FISH is a targeted approach
with a higher resolution that allows detection of aThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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genomic regions. However, FISH requires prior know-
ledge of the regions that need to be assessed for any
given patient based on a family history or specific
clinical findings.
In addition to the common aneuploides, many sub-
microscopic chromosomal rearrangements that lead to
copy-number gains or losses have been shown to cause
distinctive and recognizable clinical phenotypes. Gen-
omic microarrays, also termed ‘molecular karyotyping’
[4], are overcoming the resolution, the locus-specific,
and the time limitations of the karyotyping and FISH
techniques. Within a decade of use, microarrays have
been recommended as the first line of assessment of the
karyotype, instead of routine banded chromosomes, for
children with developmental, intellectual, and physical
disabilities [5-8]. Prenatal detection of genomic imbal-
ances using microarrays has been demonstrated over
recent years [9-12].
Here we report a case with abnormal ultrasound
finding, both the serum screening and cell-free DNA
in maternal blood were positive for trisomy 21, the
interphase FISH of the amniotic fluid suggested the
fetus to be trisomy 21, the karyotyping of the amniotic
fluid was 46,XX,21p+, but the array comparative
genomic hybridization (aCGH) analysis demonstrated
a de novo partial trisomy 21q(21q22.12→ q22.3) and
other concomitant small duplications and deletion on
21q. The metaphase FISH of the amniotic cell chromo-
somes demonstrated that the duplication of 21q
(21q22.12→ q22.3) was located on the p arm of one of
the chromosome 21.Figure 1 G-banded karyotype shows an unknown duplication on 21pCase report
A 29-year-old gravida 1, para 0 woman came to our clinic
at 15 gestational weeks, the ultrasound showed the nuchal
fold of 0.6cm thickness and without other abnormal find-
ings. The maternal serum screening (AFP + free β-hCG +
uE3) showed the risk of fetal Down syndrome was 1/110.
We performed sequencing analysis of the cell free DNA
extracted from the maternal peripheral blood, and the
result turned out to be positive for trisomy 21.The amnio-
centesis was performed at 18 weeks of gestation. The
interphase FISH showed three signals of the probe
DSCR2:21q22. However, the amniocentesis revealed a
karyotyping of 46,XX,21p + (Figure 1). Chromosome
preparations of the blood lymphocytes from the parents
revealed normal karyotypes. The metaphase FISH analysis
with the probe DSCR2:21q22 showed that the segment of
the 21p + was 21q22 in origin (Figure 2). The aCGH
analysis demonstrated a 11.74 Mb duplication of
21q22.12-q22.3, a 1.31 Mb duplication of 21q21.3, a
1.33 Mb duplication of 21q21.1 and a 1.68 Mb deletion
of 21q21.1-21q21.2 (Figure 3). STS (sequence-tagged
site) was used to distinguish the parental origin of the
1.68 Mb deletion and the allele derived from the
mother was deleted (Figure 4).
The parents opted to terminate the pregnancy. A
malformed female fetus with some characterization of
Down syndrome was delivered with a flat facial profile,
hypertelorism, a depressed nasal bridge, a protruding
tongue, loose folds in posterior neck, and a single crease
on the right hand (Figure 5). A formal autopsy was
performed by the Department of Pathology of our hos-
pital. Besides of the above phenotypes, the subcutaneous.
Figure 2 Fluorescence in situ hybridization analysis using the
probe DSCR2:21q22 showed that the segment of the 21p + was
21q22 in origin. Figure 3 aCGH results indicated there were three duplications
and one deletion in 21q. The largest duplicated region of 11.74
Mb extending from 21q22.12 to 21q22.3, which should contribute to
the fetus clinical characterization of Down syndrome.
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malities of the heart or the other organs were found.
Discussion
We have presented prenatal molecular cytogenetic
characterization of a second trimester fetus with some
clinical features of Down syndrome resulting from a
partial trisomy 21q due to a de novo duplication of
21q22.12→ q22.3. The aCGH analysis demonstrated
that the present case had a duplication of 21q22.12→
22.3 (chr21:36326031–48067924) (11.74 Mb), a duplication
of 21q21.3 (chr21: 26975925–28285899) (1.31 Mb), a dupli-
cation of 21q21.1 (chr21: 18867555–20196174) (1.33 Mb)
and a deletion of 21q21.1 - q21.2 (chr21: 23127142–
24811889) (1.68 Mb). The complex rearrangements in the
21 chromosome in this case don't belong to interstitial
inverted duplication with concomitant terminal deletion,
which was frequently caused by U-type exchange.
Reviewing all the proposed mechanisms, it is still diffi-
cult to interpret the mechanism for the complex re-
arrangement happened on this case. Down syndrome
involving a duplication of the Down syndrome critical
region (DSCR) accounts for less than 1% of the cases
with Down syndrome [13]. DSCR is the critical region
on chromosome 21 of which the duplication is respon-
sible for the majority of phenotypic features in Down
syndrome.
The duplication of 21q21.3(chr21: 26975925–28285899)
(1.31 Mb) encompasses the gene APP (OMIM 104760),
which accounts for the phenotype of familial Alzheimer
disease 1 and cerebral amyloid angiopathy. We now knowthat essentially all individuals with Down syndrome
develop Alzheimer disease-like pathology by the fourth
decade of life. APP (amyloid beta A4 precursor protein)
(gene map at 21q21.3) gene is found in the Down syn-
drome obligate region, and the protein is overexpressed
in the adult Down syndrome brain [14,15]. One of the
patients characterized, a 65-year old without an additional
copy of APP, did not have dementia or indication of
amyloid accumulation when assessed by brain imaging,
supporting a causative role for APP overexpression in
neuropathology in Down syndrome [16]. Overexpression
of APP leads to dysfunction of the endocytic system,
increased amounts of APP in the Down syndrome brain
result in increased amounts of β-amyloid (Aβ) and extra-
cellular plaque formation beginning early in life, which is
the main driver of Alzheimer Disease-like pathology in the
brains of elderly Down syndrome individuals [17,18].
The duplication of 21q21.1(chr21: 18867555-20196174)
(1.33 Mb) encompasses the gene ENTK(OMIM 606635).
ENTK (enterokinase) is an intestinal enzyme responsible
for initiating activation of pancreatic proteolytic proen-
zymes (trypsin, chymotrypsin and carboxypeptidase A).
It is reasonable to deduce that this region has no correl-
ation with the phenotype and pathophysiology of Down
syndrome.
The duplication of 21q22.12→ 22.3 (chr21: 36326031–
48067924)(11.74 Mb) (Figure 6) encompasses some
disease-causing genes, such as DYRK1A (OMIM 600855),
Figure 5 (A) Facial profile, hypertelorism, a depressed nasal
bridge, a protruding tongue and (B) a single crease on the
right hand at birth.
Figure 4 The Polyacrylamide Gel Electrophoresis (PAGE) results
showed that the DNA band of the fetus was the same as
father’s, but was lack of the mother’s band. This indicates that
the allele derived from his mother was deleted. M: maternal; P:
Paternal; F: Fetus.
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HLCS (OMIM 609018), COL18A1 (OMIM 120328) and
PCNT (OMIM 605925). Among these genes, DYRK1A
(OMIM 600855) is associated with the pathophysiology
of Down syndrome. DYRK1A (dual-specificity tyrosine
phosphorylation-regulated kinase 1A) (gene map at
21q22.1) encodes a member of the dual-specificity tyro-
sine phosphorylation-regulated kinase family and partic-
ipates in various cellular processes. It is a highly
conserved gene located in the DSCR region [19].
DYRK1A has been suggested to be involved in the
abnormal neurogenesis found in Down syndrome [20].
Arron et al., [21] reported that 2 genes, DSCR1 (OMIM
602917) and DYRK1A act synergistically to prevent nuclear
occupancy of NFATc(OMIM 600489) transcription factors,
which are regulators of vertebrate development. The 1.5-
fold increase in dosage of DSCR1 and DYRK1A coopera-
tively destabilizes a regulatory circuit, leading to reduced
NFATc activity and many of the features of Down syn-
drome. Overexpression of DSCR1 will inhibit calcineurin
activity and causes accumulation of hyperphosphorylated
tau protein and production of neurofibrillary tangles caus-
ing Alzheimer’s disease [22]. Ryoo et al., [23] showed that
mice overexpressing human DYRK1A had elevated levels
of threonine-phosphorylated tau, which is found in insol-
uble neurofibrillary tangles in Alzheimer disease brains.
DYRK1A phosphorylated tau on threonine and serine resi-
dues in vitro. Phosphorylation of tau by DYRK1A reduced
the ability of tau to promote microtubule assembly. Ryoo
et al., [23] concluded that an extra copy of DYRK1A can
contribute to early onset of Alzheimer disease.
As to the deletion of 21q21.1 - q21.2 (chr21: 23127142–
24811889) (1.68 Mb), there was no OMIM gene within
this region. It is reasonable to deduce that this region has
no correlation with the phenotype and pathophysiology of
Down syndrome.To date, at least 39 cases of Down syndrome with pure
partial tirsomy 21 have been reported [24,25], but the pre-
natal diagnosis of pure partial trisomy 21q associated with
Down syndrome is quite rare. Lee et al., [26] reported a
case of prenatal diagnosis of pure trisomy 21q(21q13→
q22.2) due to an unbalanced cryptic insertion (4;21)(q21;
q22.1q22.3) inherited from the carrier father. The fetus
had a karyotype of 46,XX,der(4)ins(4;21)(q21;q22.13q22.2)
pat. The abnormal prenatal findings included a maternal
serum screening Down syndrome risk of 1:17 and a thick
nuchal fold. The fetus was delivered with clinical features of
Down syndrome. Chen et al., [27] reported a case of pre-
natal diagnosis and molecular cytogenetic characterization
of de novo partial trisomy 21q(21q22.11→ qter) associated
with clinical features of Down syndrome. Oligonucleotide-
based aCGH demonstrated a 14.8 Mb duplication of distal
21q. The karyotype of the fetus was 46,XX,der(9)t(9;21)
(q34.3;q22.11). The abnormal prenatal finding included an
abnormal level II ultrasound at 20 weeks of gestation of
clinodactyly and hypoplastic midphalanx of the fifth fingers,
midface hypoplasia and an intracardiac echogenic focus.
Figure 6 This is the screenshot from the UCSC genome browser for the fragment of 21q22.12→ 22.3. For Decipher Database, the entries
of clinical cases are in red for deletions (mean log ratio < 0) and in blue for duplications (mean log ratio > 0). For Database of Genome Variants
(DGV struct Var), inversions are in purple, whereas InDels are in blue if there is a gain in size relative to the reference, in red if there is a loss in
size or in brown if there are reports of both a loss and a gain in size.
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fetus. The maternal serum screening (AFP + free
β-hCG + uE3) showed the risk of fetal DS was 1/110.
The following analysis of cell-free DNA in maternal
blood turned out to be positive for trisomy 21. FISH
analysis of amniotic fluid demonstrated a duplication of
21q22 on the short arm of the chromosome 21. Array-
based CGH analysis demonstrated a 11.74 Mb duplication
on 21q22.12→ 22.3 (chr21: 36326031–48067924) and a
1.31 Mb duplication on 21q21.3(chr21: 26975925–
28285899). These two regions encompass the genes asso-
ciated with the phenotype and pathopysiology of Down
syndrome.
Prenatal studies in ongoing pregnancies using aCGH
has been developed quickly in the recent years. Hillman
et al., [28] recently performed a meta-analysis of eight
studies of array findings in prenatal diagnosis. The
meta-analysis found that microarray testing increased
the detection of chromosome abnormalities by 2.9%
over routine karyotyping. Recently Shaffer et al., [29]
reviewed their results of prenatal diagnosis in over 5000
pregnancies with micro-array based comparative gen-
omic hybridization. The overall detection rate of clinic-
ally significantly copy number alterations amongunbiased, nondemised cases was 5.3%. Detection rate
was 6.5% for cases referred with abnormal ultrasounds.
The author concluded that the microarray testing
should be considered a first-tier test for the diagnosis of
cytogenetic aberrations in the fetus. Current ACOG
guidelines suggest that karyotypic analysis by aCGH
should be considered as an adjunct rather than a
replacement for conventional karyotyping [30]. In that
opinion paper, they recommended that microarray test-
ing should be limiting to those pregnancies that show
abnormal ultrasound findings and that it should be
performed in conjunction with a routine banded karyo-
type. In this case report, aCGH is the useful tool to
demonstrate the de novo chromosomal abnormality of
the fetus when the ultrasound showed the abnormally
thickening of the nuchal fold of the fetus, this also
supports the current guideline of ACOG.
In conclusion, aCGH is useful for rapid identification of
the genomic imbalance associated with de novo alterations
in small fragments of the chromosome, and FISH is also
useful in prenatal investigation of the nature of a de novo
alterations of the chromosome. The combination of ultra-
sound and the molecular cytogenetic analysis are essential
for the prenatal diagnosis of partial trisomy 21q.
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Chromosome analysis
Chromosome analysis using GTG-banding was done
according to standard procedures. A total of 20 metaphase
cells were analyzed. Karyotypes were described according




FISH using red color probe (GLP 21 probe kit, Beijing
GPmedical technologies, Ltd, Beijing, China) was applied
according to manufacturer’s instructions. A total of 100
interphase amniotic cells and 20 metaphase spreads were
analyzed respectively.
cffDNA analysis
For cell-free DNA analysis, 5 ml peripheral blood was
drawn into an EDTA containing Vacutainer tube. Within 6
hours of blood collection, plasma was separated and plasma
DNA was extracted using the QIAamp Circulating Nucleic
Acid kit from Qiagen (Hilden, Germany). The sequencing
analysis was conducted at Berry Genomics Co, Ltd., located
in Beijing, China. Plasma DNA was used as the input DNA
to make a library for sequencing analysis, using a modified
ChIP Seq protocol. For chromosome 21 of each sample,
the Z scores (cutoff = 3) were calculated to determine if a
sample is aneuploidy as reported previously [31].
aCGH analysis
Genomic DNA was extracted from 10 ml of amniotic fluid
with a commercially available Amniotic Fluid Genomic
DNA Extraction Kit (BioChain Institute Inc., Newark, CA)
according to the manufacturer's instructions. For each
aCGH experiment, 400 ng of genomic DNA and normal
female DNA (BioChain Institute) was digested with 10 U
Alu I and 10 U Rsa I (Promega, Madison, WI) and differ-
entially labeled with cyanine-5 (cy5) and cyanine-3 (Cy3)
fluorescent dyes using a Genomic DNA Enzymatic Label-
ing Kit (Agilent, Santa Clara, CA). The aCGH analysis was
performed using 8 × 60 K commercial arrays (Agilent).
This platform contains 60-mer oligonucleotide probes
spanning the entire human genome with an overall mean
probe spacing of 50 kb. After hybridization, the arrays
were scanned using a dual-laser scanner (Agilent) and
the images were extracted and analyzed using Feature
Extraction software (Agilent) and Workbench genomics
software, respectively.
Confirmation the deletion of 21q21.1 - q21.2 using STS
markers
STS (sequence-tagged site) is a short DNA sequence that
has a single occurrence in the genome and whose location
and base sequence are known. It can easily be used todistinguish individuals and detect microdeletions. Since
aCGH result indicated that there was a 1.68 Mb deletion
in 21q21.1-21q21.2 between two duplication fragment,
which was generally rare to happen, eight STS markers
located on the deletion region were selected from UniSTS
database [http://www.ncbi.nlm.nih.gov/unists/] for PCR
amplification from the parents and amniotic fluid to
validate the 1.68 Mb deletion. The Polyacrylamide Gel
Electrophoresis (PAGE) results showed that only D21S1409
was informative for deciphering the allelic origin of the
deletion. The DNA band of the fetus was the same as
father’s, but was lack of the mother’s band. This indicates
that the allele derived from his mother was deleted
(Figure 4).
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